Company Valuation: GlaxoSmithKline Pakistan Limited

Data adjusted to current consolidation scope
Fiscal Period: December 2024 2025 2026 2027 2028
Market Cap 1 126,403 124,132 116,842 - -
Change - -1.8% -5.87% - -
Enterprise Value (EV) 126,403 124,132 116,842 116,842 116,842
Change - -1.8% -5.87% 0% 0%
P/E 19.3x 12.4x 10.6x 9.08x 8.1x
PBR - 3.69x 2.69x 2.32x 2.03x
PEG - 0.2x 1.11x 0.5x 0.7x
Capitalization / Revenue - 1.88x 1.7x 1.57x 1.43x
EV / Revenue - 0x 1.7x 1.57x 1.43x
EV / EBITDA - - - - -
EV / EBIT - - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Dividend per Share 2 - 17 18.56 20.81 23.5
Rate of return - 4.36% 5.06% 5.67% 6.41%
EPS 2 20.52 31.48 34.48 40.4 45.27
Distribution rate - 54% 53.8% 51.5% 51.9%
Net sales 1 - 65,901 68,813 74,577 81,779
EBITDA - - - - -
EBIT - - - - -
Net income 1 6,536 10,025 10,490 12,420 14,268
Net Debt - - - - -
Reference price 2 396.91 389.78 366.89 366.89 366.89
Nbr of stocks (in thousands) 318,467 318,467 318,467 - -
Announcement Date 3/24/25 3/26/26 - - -
1PKR in Million2PKR
Estimates

P/E, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
10.64x - - 5.06% 420M
32.86x12x24.39x0.61% 1,006B
26.17x6.03x16.39x2.18% 589B
30.87x7.21x14.74x2.85% 430B
17.87x4.45x10.93x2.99% 331B
23.29x4.86x13.76x1.8% 288B
21.56x5.56x13.49x2.84% 285B
13.98x5.17x10.65x3.6% 213B
22.94x6.13x10.71x2.86% 190B
-44.37x5.36x29.56x2.62% 154B
Average 15.58x 6.31x 16.07x 2.74% 348.62B
Weighted average by Cap. 23.24x 7.53x 17.44x 2.05%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. Valuation GlaxoSmithKline Pakistan Limited